ArticleCureus2026
"No Touch to Touch": Percutaneous Sclerotherapy of a Giant Hepatic Cavernous Hemangioma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cavernous hemangiomas were originally taught as "no touch lesions" as they were benign, hypervascular, venous malformations. They are commonly found in the liver. Patients typically present asymptomatically, and these hemangiomas can be found incidentally on imaging as solitary or multiple lesions. A 42-year-old male patient arrived at our institution after a motor vehicle collision, and a giant hemangioma was found incidentally on imaging with a classic feature of peripheral nodular enhancement on arterial phase computed tomography (CT) imaging. However, the patient continued to report right upper quadrant pain. Given the patient's age and size of the lesion, percutaneous sclerotherapy using bleomycin and lipiodol was performed. At the two-week follow-up, the patient denied fever, nausea, vomiting, or pain. At six months, the patient was asymptomatic, and follow-up CT angiography (CTA) demonstrated an approximately 50% reduction in lesion size. Therefore, percutaneous sclerotherapy is an effective, low-risk, and technically straightforward treatment alternative to the traditional intraarterial approach, resulting in significant lesion size reduction and meaningful symptomatic relief with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.